Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.
A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.